GlobeNewswire: VBI Vaccines, Inc. Contains the last 10 of 115 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:43:25ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/09/05/1911459/0/en/VBI-Vaccines-to-Present-at-the-H-C-Wainwright-21st-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=39997VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference2019-09-05T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York City on Tuesday, September 10, 2019, at 8:20 AM ET.]]>https://www.globenewswire.com/news-release/2019/08/09/1899900/0/en/VBI-Vaccines-Announces-Second-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=39997VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update2019-08-09T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Aug. 09, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the second quarter ending June 30, 2019, and provided an update on the Company’s recent and future developments.]]>https://www.globenewswire.com/news-release/2019/08/05/1896803/0/en/VBI-Vaccines-to-Present-at-the-Canaccord-Genuity-39th-Annual-Growth-Conference.html?f=22&fvtc=4&fvtv=39997VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Conference2019-08-05T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA, on Thursday, August 8, 2019, at 1:30 PM ET.]]>https://www.globenewswire.com/news-release/2019/07/29/1892800/0/en/VBI-Vaccines-Announces-Dosing-of-First-Recurrent-GBM-Patient-in-Part-B-of-Ongoing-Phase-1-2a-Study-of-VBI-1901.html?f=22&fvtc=4&fvtv=39997VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-19012019-07-29T12:00:00Z<![CDATA[— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded immunologic data and tumor and clinical responses expected H1 2020]]>https://www.globenewswire.com/news-release/2019/07/01/1876623/0/en/VBI-Vaccines-Added-to-Russell-2000-and-Russell-3000-Indexes.html?f=22&fvtc=4&fvtv=39997VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes2019-07-01T12:00:00Z<![CDATA[CAMBRIDGE, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced today that it has been added to the Russell 2000® and the Russell 3000® Indexes following the annual reconstitution, effective after the US market opens on Monday, July 1, 2019.]]>https://www.globenewswire.com/news-release/2019/06/20/1871803/0/en/VBI-Vaccines-to-Present-at-the-BMO-Capital-Markets-2019-Prescriptions-for-Success-Healthcare-Conference.html?f=22&fvtc=4&fvtv=39997VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference2019-06-20T12:00:00Z<![CDATA[CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will participate in an analyst-led fireside chat at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019, at 11:20 AM ET in New York City.]]>https://www.globenewswire.com/news-release/2019/06/17/1869447/0/en/VBI-Vaccines-Announces-Positive-Top-Line-Results-from-PROTECT-a-Pivotal-Phase-3-Study-of-Sci-B-Vac.html?f=22&fvtc=4&fvtv=39997VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®2019-06-17T10:00:00Z<![CDATA[CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive top-line results from the randomized, double-blind, pivotal Phase 3 study, PROTECT, designed to evaluate the efficacy and safety of a 10 µg dose of Sci-B-Vac®, the company’s trivalent hepatitis B vaccine, compared with a 20 µg dose of the comparator vaccine, Engerix-B®.]]>https://www.globenewswire.com/news-release/2019/06/16/1869304/0/en/VBI-Vaccines-to-Host-Conference-Call-Tomorrow-to-Review-PROTECT-Phase-3-Clinical-Data-for-Sci-B-Vac.html?f=22&fvtc=4&fvtv=39997VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac® 2019-06-16T16:00:00Z<![CDATA[CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine.]]>https://www.globenewswire.com/news-release/2019/06/13/1868725/0/en/VBI-Vaccines-Announces-Results-of-Annual-General-Meeting.html?f=22&fvtc=4&fvtv=39997VBI Vaccines Announces Results of Annual General Meeting2019-06-13T21:00:00Z<![CDATA[CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on June 13, 2019 (the "Meeting").]]>https://www.globenewswire.com/news-release/2019/06/04/1863878/0/en/VBI-Vaccines-Reports-Data-from-Part-A-of-the-Ongoing-Phase-1-2a-Study-of-VBI-1901-in-Recurrent-Glioblastoma-GBM-Patients-at-ASCO-2019.html?f=22&fvtc=4&fvtv=39997VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 20192019-06-04T12:00:00Z<![CDATA[]]>